AGA临床实践更新:萎缩性胃炎的诊断与管理专家综述
美国胃肠病协会发布临床实践更新,针对幽门螺杆菌感染或自身免疫所致的萎缩性胃炎提出12条最佳实践建议,涵盖组织学确诊、内镜识别与活检、幽门螺杆菌根除、监测间隔及自身免疫相关筛查,旨在改善这一癌前病变的识别与风险分层。
要点
- 萎缩性胃炎诊断需组织病理学确认,肠化生几乎均提示萎缩性胃炎。
- 内镜应识别黏膜苍白、血管透见、皱襞消失等特征,并分开活检胃体与胃窦/角。
- 所有萎缩性胃炎患者均应检测幽门螺杆菌,阳性者根除并确认成功。
核心结论
- 萎缩性胃炎是胃癌多步级联中的重要癌前阶段,应基于组织病理学确诊并进行风险分层。
- 建议涵盖幽门螺杆菌根除、内镜监测及自身免疫相关缺陷筛查,以改善临床管理。
研究设计与样本
- 美国胃肠病协会临床实践更新专家综述,基于已发表文献证据与共识专家意见制定。
- 未对证据强度或质量进行正式评级,旨在为美国临床医生提供实用建议。
主要发现
- 萎缩性胃炎定义为慢性炎症背景下胃腺体丢失,伴或不伴化生,主要由幽门螺杆菌感染或自身免疫所致。
- 肠化生在组织学上几乎均提示萎缩性胃炎,胃肠病学家与病理学家应协调记录萎缩的范围和严重程度。
- 内镜典型特征包括黏膜苍白、血管透见增加、胃皱襞消失,伴肠化生时可见淡蓝色嵴和白色不透明区。
关键数值与推荐
- 建议1:萎缩性胃炎诊断需组织病理学确认。
- 建议4:活检至少取胃体和胃窦/角并分瓶放置,对可疑萎缩/化生区域及异常黏膜行靶向活检。
- 建议6:所有萎缩性胃炎患者检测幽门螺杆菌,阳性者治疗并用非血清学方法确认根除。
- 建议7:晚期萎缩性胃炎(基于解剖范围和組織学分级)可考虑每3年监测内镜。
- 建议10:自身免疫性胃炎患者筛查1型胃神经内分泌肿瘤,小肿瘤内镜下切除后每1-2年监测内镜。
临床怎么用
- 临床医生应识别萎缩性胃炎的内镜特征并规范活检,组织学确诊后评估幽门螺杆菌感染并根除。
- 自身免疫性胃炎患者应检查抗壁细胞抗体和抗内因子抗体,评估维生素B12和铁缺乏,并筛查自身免疫甲状腺疾病。
- 监测间隔应基于个体风险评估和共享决策,晚期萎缩性胃炎可考虑每3年一次内镜监测。
局限性
- 最佳实践建议基于文献证据与专家共识,未对证据强度或质量进行正式评级。
- 萎缩性胃炎的最佳内镜监测间隔尚未明确,自身免疫性胃炎的监测间隔亦不清晰。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: The purpose of this Clinical Practice Update Expert Review is to provide clinicians with guidance on the diagnosis and management of atrophic gastritis, a common preneoplastic condition of the stomach, with a primary focus on atrophic gastritis due to chronic Helicobacter pylori infection-the most common etiology-or due to autoimmunity. To date, clinical guidance for best practices related to the diagnosis and management of atrophic gastritis remains very limited in the United States, which leads to poor recognition of this preneoplastic condition and suboptimal risk stratification. In addition, there is heterogeneity in the definitions of atrophic gastritis, autoimmune gastritis, pernicious anemia, and gastric neoplasia in the literature, which has led to confusion in clinical practice and research. Accordingly, the primary objective of this Clinical Practice Update is to provide clinicians with a framework for the diagnosis and management of atrophic gastritis. By focusing on atrophic gastritis, this Clinical Practice Update is intended to complement the 2020 American Gastroenterological Association Institute guidelines on the management of gastric intestinal metaplasia. These recent guidelines did not specifically discuss the diagnosis and management of atrophic gastritis. Providers should recognize, however, that a diagnosis of intestinal metaplasia on gastric histopathology implies the diagnosis of atrophic gastritis because intestinal metaplasia occurs in underlying atrophic mucosa, although this is often not distinctly noted on histopathologic reports. Nevertheless, atrophic gastritis represents an important stage with distinct histopathologic alterations in the multistep cascade of gastric cancer pathogenesis. METHODS: The Best Practice Advice statements presented herein were developed from a combination of available evidence from published literature and consensus-based expert opinion. No formal rating of the strength or quality of the evidence was carried out. These statements are meant to provide practical advice to clinicians practicing in the United States. Best Practice Advice Statements BEST PRACTICE ADVICE 1: Atrophic gastritis is defined as the loss of gastric glands, with or without metaplasia, in the setting of chronic inflammation mainly due to Helicobacter pylori infection or autoimmunity. Regardless of the etiology, the diagnosis of atrophic gastritis should be confirmed by histopathology. BEST PRACTICE ADVICE 2: Providers should be aware that the presence of intestinal metaplasia on gastric histology almost invariably implies the diagnosis of atrophic gastritis. There should be a coordinated effort between gastroenterologists and pathologists to improve the consistency of documenting the extent and severity of atrophic gastritis, particularly if marked atrophy is present. BEST PRACTICE ADVICE 3: Providers should recognize typical endoscopic features of atrophic gastritis, which include pale appearance of gastric mucosa, increased visibility of vasculature due to thinning of the gastric mucosa, and loss of gastric folds, and, if with concomitant intestinal metaplasia, light blue crests and white opaque fields. Because these mucosal changes are often subtle, techniques to optimize evaluation of the gastric mucosa should be performed. BEST PRACTICE ADVICE 4: When endoscopic features of atrophic gastritis are present, providers should assess the extent endoscopically. Providers should obtain biopsies from the suspected atrophic/metaplastic areas for histopathological confirmation and risk stratification; at a minimum, biopsies from the body and antrum/incisura should be obtained and placed in separately labeled jars. Targeted biopsies should additionally be obtained from any other mucosal abnormalities. BEST PRACTICE ADVICE 5: In patients with histology compatible with autoimmune gastritis, providers should consider checking antiparietal cell antibodies and anti-intrinsic factor antibodies to assist with the diagnosis. Providers should also evaluate for anemia due to vitamin B-12 and iron deficiencies. BEST PRACTICE ADVICE 6: All individuals with atrophic gastritis should be assessed for H pylori infection. If positive, treatment of H pylori should be administered and successful eradication should be confirmed using nonserological testing modalities. BEST PRACTICE ADVICE 7: The optimal endoscopic surveillance interval for patients with atrophic gastritis is not well-defined and should be decided based on individual risk assessment and shared decision making. A surveillance endoscopy every 3 years should be considered in individuals with advanced atrophic gastritis, defined based on anatomic extent and histologic grade. BEST PRACTICE ADVICE 8: The optimal surveillance interval for individuals with autoimmune gastritis is unclear. Interval endoscopic surveillance should be considered based on individualized assessment and shared decision making. BEST PRACTICE ADVICE 9: Providers should recognize pernicious anemia as a late-stage manifestation of autoimmune gastritis that is characterized by vitamin B-12 deficiency and macrocytic anemia. Patients with a new diagnosis of pernicious anemia who have not had a recent endoscopy should undergo endoscopy with topographical biopsies to confirm corpus-predominant atrophic gastritis for risk stratification and to rule out prevalent gastric neoplasia, including neuroendocrine tumors. BEST PRACTICE ADVICE 10: Individuals with autoimmune gastritis should be screened for type 1 gastric neuroendocrine tumors with upper endoscopy. Small neuroendocrine tumors should be removed endoscopically, followed by surveillance endoscopy every 1-2 years, depending on the burden of neuroendocrine tumors. BEST PRACTICE ADVICE 11: Providers should evaluate for iron and vitamin B-12 deficiencies in patients with atrophic gastritis irrespective of etiology, especially if corpus-predominant. Likewise, in patients with unexplained iron or vitamin B-12 deficiency, atrophic gastritis should be considered in the differential diagnosis and appropriate diagnostic evaluation pursued. BEST PRACTICE ADVICE 12: In patients with autoimmune gastritis, providers should recognize that concomitant autoimmune disorders, particularly autoimmune thyroid disease, are common. Screening for autoimmune thyroid disease should be performed.
引用
- Shah SC, Piazuelo MB, Kuipers EJ, et al. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology. 2021. PMID: 34454714. doi:10.1053/j.gastro.2021.06.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。